IL-PROJECT44
14.9.2021 10:32:07 CEST | Business Wire | Press release
project44 , the leader in real-time supply chain visibility and a Google Premier Visibility Provider, today announced a new partnership with Google Cloud to provide customers with better, real-time visibility into their supply chains. Under this partnership, project44 will be the first strategic partner for real-time transportation visibility to integrate its capabilities into Google Cloud’s Supply Chain Twin solution to provide joint customers with a view into the supply chain network, including data across all modes, existing integrations at scale, and strong relationships with other partners included in the offering.
“We’re excited to team up with project44 as the first strategic partner for real-time visibility in Google Cloud’s Supply Chain Twin solution. project44’s broad visibility network, workflow automation and predictive analytics enable collaboration across all facets of the supply chain,” said Hans Thalbauer, managing director, global supply chain and logistics industry solutions for Google Cloud. “project44’s incredible expertise in transportation provides customers with the technology needed to greatly improve insight into shipments and orders across their supply chain.”
Google Cloud supply chain solutions, particularly the Supply Chain Twin, deliver end-to-end visibility by bringing together data from various business systems such as enterprise resource planning (ERP), transportation management systems (TMS), and warehouse management systems (WMS), as well as data from the operational systems of the customer and those of their partners. The increased transportation visibility and reporting provided by project44 will provide customers with visibility into data relating to shipments once they have left suppliers, as well as when inventory is moving between warehouses and manufacturing plants, and into customers’ hands.
The project44 Platform currently supports more than 680 global shippers and logistics service providers, providing visibility into a network of more than 113,500 multimodal carrier integrations and 2.6M assets – the largest carrier network available in a single platform today.
“It’s incredibly validating to be selected as the first strategic visibility partner for Google Cloud and its new Supply Chain Twin solution,” said Jett McCandless, CEO and founder of project44. “Taking an integrated, data-first approach to solving the world’s most complex supply chain challenges will have significant benefits for customers who rely on accurate, real-time data to deliver outstanding experiences for their own customers.”
A Partnership for Growth
project44 is the fastest growing SaaS platform for real-time, end-to-end transportation visibility. Integrating with Google Cloud’s Supply Chain Twin is the latest step in project44’s aggressive plans which focus on organic growth, strategic acquisitions and partnerships, and geographic expansion. Having project44 data on Google Cloud’s BigQuery builds on their shared vision of highly available access to data and data-led decision making to improve operations as both customer expectations and supply chain disruptions keep rising.
Named as a Leader in the 2021 Gartner Magic Quadrant for Real-time Transportation Visibility , project44 continues to invest in platform, ecosystem and data science capabilities that deliver the most complete end-to-end supply chain visibility. The company announced record growth in Q2, including enterprise net dollar retention of 129% and 123% year-over-year growth in ARR. Already the largest visibility platform company as measured by ARR, customer count, and carriers, project44’s ARR in Q2 was more than the sum of the next top six visibility companies combined for the same quarter.
For more information on the Google Cloud Supply Chain Twin powered by project44, click here .
About project44
project44 is the world’s leading advanced visibility platform for shippers and logistics service providers. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional experience to their customers. Connected to thousands of carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Air, Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Groupage, Truckload, Rail, Intermodal, and Ocean. In 2021, project44 was named a Leader among Real-Time Transportation Visibility Providers in Gartner’s Magic Quadrant. To learn more, visit project44.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005253/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom